Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) reached a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $16.51 and last traded at $16.67, with a volume of 22375 shares. The stock had previously closed at $17.79.
Rapport Therapeutics Stock Down 6.1 %
The company has a 50-day moving average of $21.01.
Institutional Trading of Rapport Therapeutics
Several institutional investors have recently bought and sold shares of the company. Values First Advisors Inc. purchased a new stake in shares of Rapport Therapeutics during the 3rd quarter valued at about $31,000. BNP Paribas Financial Markets purchased a new stake in Rapport Therapeutics in the third quarter worth approximately $34,000. JPMorgan Chase & Co. purchased a new stake in Rapport Therapeutics in the third quarter worth approximately $83,000. SG Americas Securities LLC bought a new stake in Rapport Therapeutics in the 3rd quarter worth approximately $101,000. Finally, Sandia Investment Management LP purchased a new stake in Rapport Therapeutics during the 2nd quarter valued at $116,000.
About Rapport Therapeutics
(
Get Free Report)
Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.
Featured Articles
Before you consider Rapport Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rapport Therapeutics wasn't on the list.
While Rapport Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
